StockData
Eton Pharmaceuticals, Inc. logo

Eton Pharmaceuticals, Inc. (ETON) company profile

ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30524% above fair value
$63.65−0.23 (-0.36%)

Close on Nov 17, 2026Market cap $1.82BP/E 163.2Yield –

About Eton Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Eton Pharmaceuticals is a pharmaceutical company that develops and commercializes treatments for rare diseases. The company operates primarily in the endocrinology and metabolic disease segments. Its commercial portfolio comprises eight approved therapies, including Increlex, Alkindi Sprinkle, Khindivi, Galzin, and PKU Golike, as well as generic formulations of carglumic acid, betaine anhydrous, and nitisinone. These medications address conditions such as adrenocortical insufficiency, growth factor deficiency, Wilson disease, and genetic metabolic disorders. The company's end consumers are rare disease patients, often children, and it distributes its therapies through specialty pharmacies to healthcare providers and patients.

The company conducts its commercial sales operations in the United States, and its product Increlex is approved in forty international territories, including the European Union. Eton maintains twelve employees supporting its research and development initiatives. It outsources finished product manufacturing to third-party contract manufacturing organizations situated primarily across the United States and Europe. The provided text does not state the company's headquarters.

Summary of the business section of Eton Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Eton Pharmaceuticals, Inc.
Founded
2017
Headquarters
Deer Park, IL
Address
21925 W. Field Parkway, Suite 235 60010-7278
Phone
(847) 787-7361
Employees
44, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
GRANT THORNTON LLP, Chicago, Illinois

Stock & identifiers

Ticker
ETON
Exchange
Nasdaq
IPO date
Nov 13, 2018
Shares outstanding
29M, Aug 11, 2026
Public float
$360.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1710340
CUSIP
29772L108
ISIN
US29772L1089
FIGI
BBG00H0KCMV1
Share class FIGI
BBG00H0KCMW0
EIN
37-1858472

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Sean BrynjelsenPresident & CEO, Director1,029,849
Ipek Erdogan-TrinkausChief Commercial Officer4,081
David KrempaChief Business Officer43,381
Danka RadosavljevicChief Operating Officer22,473
Judith M. MatthewsChief Financial Officer–
James R. GruberChief Financial Officer213,420
Charles J. CasamentoDirector0
Paul V. MaierDirector73,358
Jennifer McKie AdamsDirector0
Norbert G. RiedelDirector204,645

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.91M$6.90M$1.12M––
FY2024$2.41M$7.91M$1.06M––
FY2023$1.75M$2.26M$752.11K––
FY2022$2.12M$1.70M$814.83K––

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Sean E. Brynjelsen
President and Chief Executive Officer
$712.43K$936.05K$893.71K$354.79K$17.50K$2.91M+21%
James R. Gruber
Chief Financial Officer
$460.46K$336.39K$321.17K$171.98K$108.07K$1.40M+30%
David C. Krempa
Chief Business Officer
$460.46K$336.39K$321.17K$171.98K$104.74K$1.39M+5%
Ipek Erdogan-Trinkaus
Chief Commercial Officer
$402.72K––$150.42K$22.15K$575.29K-26%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 13, 2018
Offer price
$6.00
Securities offered
3,600,000
Gross proceeds
$21.60M
Exchange
Nasdaq
First trading day
Nov 13, 2018
First-day close
$6.25+4.2%
Lock-up ends (est.)
May 12, 2019

“The initial public offering price is $6.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“At December 31, 2025, we had 44 full-time employees, twelve of whom are engaged in research and development activities, twenty-four are engaged in sales and marketing operations and eight of whom are engaged in general corporate and strategy roles.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?